drugset / Trial / NCT00770731
Study of Temsirolimus, Topotecan, and Bortezomib
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of Torisel (temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade (bortezomib) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety of this drug combination will also be studied.
Timeline
- Start
- 2008-09
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 0.3 mg/m2 | Intravenous |
| Subject | Temsirolimus | Small molecule | 5 mg | Intravenous |
| Subject | Topotecan | Small molecule | 0.8 mg/m2 | Intravenous |